380380-60-9Relevant articles and documents
OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF
-
Paragraph 0204; 0205, (2022/01/04)
Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
A new class of iridium(III) complexes based on fluorine substituted 2,3′-bipyridine and pyridyltetrazolate derivatives: Synthesis, crystal structures, photoluminescent and electroluminescent properties
Liu, Denghui,Luo, Kaijun,Ni, Hailiang,Wang, Haifeng,Yang, Bo,Yang, Congling,Yu, Wenhao,Zeng, Longwei,Zhu, Weiguo
, (2020/05/13)
The new cyclometalated iridium (III) complexes, (dfpypy)2Ir(BrPyTz) (a), (dfpypy)2Ir(CF3PyTz) (b), (tfpypy)2Ir(CF3PyTz) (c), and (dfpypy)2Ir(PzTz) (d), containing fluorine-substitued 2,3′-bipyridine as the main ligands and pyridyltetrazolate or pyrazinyltetrazolate derivatives as ancillary ligand were synthesized and characterized. The investigation of the crystal structures shows that there are intermolecular interactions in the iridium (III) complexes, including π - π stacking, the weak non - classical C–H?N hydrogen bonds and F … π interactions. Moreover, the UV–vis spectra display concentration-dependent character. As the solution concentration increases, two weak lower-energy absorption bands appear, suggesting there are aggregates between the ground state molecules. All complexes, except d that has emission peak at 467 nm, exhibit the blue photoluminescence (PL) with emission peak at about 440 nm in dichloromethane solution, but the films doped 10 wt % the complexes in polymethyl methacrylate (PMMA) show widened and distinctly tailed PL spectra between 500 and 650 nm, indicating there are the emission originated from aggregates. The organic light-emitting diodes (OLEDs) using a as emitters were fabricated by the vacuum evaporation process. Interestingly, we found that OLEDs doped with 5 wt % a show the voltage-dependent electroluminescent (EL) characteristics. At lower driving voltage EL spectra are basically the same as PL spectra in the solutions, the devices exhibit blue emission with Commission Internationale de L'Eclairage (CIE) coordinates of (0.23,0.32). On the other hand, at higher driving voltage in addition to blue emission from the monomer, there is the broadened red-shifted emission with a peak value of 560 nm originated from the aggregates. The emission from the monomer and the aggregates are well matched to produce white OLEDs with CIE coordinates (0.33,0.39). Furthermore, as the applied voltage is further increased, the blue emission from the monomer is suppressed efficiently and the devices display the yellow emission derived from the aggregates with CIE value of (0.44,0.45).
PREPARATION METHOD OF INTERMEDIATE FOR OXAZOLIDINONE DERIVATIVE
-
Paragraph 47; 48; 49; 50, (2017/07/06)
Disclosed is a method of preparing an intermediate for an oxazolidinone derivative, which enables 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine to be produced at high yield and high purity, thus exhibiting high preparation efficiency under optimal processing conditions and making it suitable for industrial mass production.
